These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 17088950)
1. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Ueda S; Yamagishi S; Takeuchi M; Kohno K; Shibata R; Matsumoto Y; Kaneyuki U; Fujimura T; Hayashida A; Okuda S Mol Med; 2006; 12(7-8):180-4. PubMed ID: 17088950 [TBL] [Abstract][Full Text] [Related]
2. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665 [TBL] [Abstract][Full Text] [Related]
3. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients. Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950 [TBL] [Abstract][Full Text] [Related]
4. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Shimoishi K; Anraku M; Kitamura K; Tasaki Y; Taguchi K; Hashimoto M; Fukunaga E; Maruyama T; Otagiri M Pharm Res; 2007 Jul; 24(7):1283-9. PubMed ID: 17387602 [TBL] [Abstract][Full Text] [Related]
5. Possible involvement of nuclear factor-kappaB inhibition in the renal protective effect of oral adsorbent AST-120 in a rat model of chronic renal failure. Komiya T; Miura K; Tsukamoto J; Okamura M; Tamada S; Asai T; Tashiro K; Kuwabara N; Iwao H; Yoshikawa J Int J Mol Med; 2004 Jan; 13(1):133-8. PubMed ID: 14654984 [TBL] [Abstract][Full Text] [Related]
6. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Iida S; Kohno K; Yoshimura J; Ueda S; Usui M; Miyazaki H; Nishida H; Tamaki K; Okuda S Clin Exp Nephrol; 2006 Dec; 10(4):262-7. PubMed ID: 17186330 [TBL] [Abstract][Full Text] [Related]
7. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673 [TBL] [Abstract][Full Text] [Related]
8. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611 [TBL] [Abstract][Full Text] [Related]
9. AST-120, an Oral Carbon Absorbent, Protects against the Progression of Atherosclerosis in a Mouse Chronic Renal Failure Model by Preserving sFlt-1 Expression Levels. Nakada Y; Onoue K; Nakano T; Ishihara S; Kumazawa T; Nakagawa H; Ueda T; Nishida T; Soeda T; Okayama S; Watanabe M; Kawakami R; Saito Y Sci Rep; 2019 Oct; 9(1):15571. PubMed ID: 31666542 [TBL] [Abstract][Full Text] [Related]
10. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis. Aoyama I; Enomoto A; Niwa T Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S8-14. PubMed ID: 12612943 [TBL] [Abstract][Full Text] [Related]
11. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Sanaka T; Akizawa T; Koide K; Koshikawa S Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877 [TBL] [Abstract][Full Text] [Related]
12. Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure. Owada A; Shiigai T Am J Nephrol; 1996; 16(2):124-7. PubMed ID: 8919228 [TBL] [Abstract][Full Text] [Related]
14. Preventive effects of an oral sorbent on nephropathy in rats. Aoyama I; Miyazaki T; Niwa T Miner Electrolyte Metab; 1999; 25(4-6):365-72. PubMed ID: 10681668 [TBL] [Abstract][Full Text] [Related]
15. An oral absorbent, AST-120, restores vascular growth and blood flow in ischemic muscles in diabetic mice via modulation of macrophage transition. Huang HL; Kuo CS; Chang TY; Chou RH; Chen IC; Yang FC; Chen NJ; Lin SJ; Wu CC; Huang PH J Mol Cell Cardiol; 2021 Jun; 155():99-110. PubMed ID: 33713645 [TBL] [Abstract][Full Text] [Related]
16. Oral sorbent AST-120 increases renal NO synthesis in uremic rats. Tumur Z; Niwa T J Ren Nutr; 2008 Jan; 18(1):60-4. PubMed ID: 18089446 [TBL] [Abstract][Full Text] [Related]
17. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306 [TBL] [Abstract][Full Text] [Related]
18. Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: relevance to glycoxidation damage. Meng J; Sakata N; Imanaga Y; Takebayashi S; Nagai R; Horiuchi S Nephron; 2001 May; 88(1):30-5. PubMed ID: 11340347 [TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products in children with chronic renal failure and type 1 diabetes. Misselwitz J; Franke S; Kauf E; John U; Stein G Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886 [TBL] [Abstract][Full Text] [Related]
20. Daily haemodialysis improves indices of protein glycation. Floridi A; Antolini F; Galli F; Fagugli RM; Floridi E; Buoncristiani U Nephrol Dial Transplant; 2002 May; 17(5):871-8. PubMed ID: 11981076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]